Dr. S. Vincent Rajkumar on a New Bortezomib Triplet in Multiple Myeloma
S. Vincent Rajkumar, MD, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
S. Vincent Rajkumar, MD, professor of medicine, Mayo Clinic, discusses bortezomib, lenalidomide, and dexamethasone coming out on top in a recent phase III trial over lenalidomide and dexamethasone alone.
The findings of the phase III trial, labeled SWOG S0777, showed a 13-month improvement in progression-free survival and a 29% reduction of risk of death with the triplet of bortezomib, lenalidomide, and dexamethasone, compared with lenalidomide and dexamethasone alone. Findings from the study suggest the triplet should be a new standard of care for untreated patients with multiple myeloma. Rajkumar said the triplet is now the new standard of care at the Mayo Clinic for multiple myeloma.
Conservative Management Is on the Rise in Intermediate-Risk Prostate Cancer
January 17th 2025In an interview with Peers & Perspectives in Oncology, Michael S. Leapman, MD, MHS, discusses the significance of a 10-year rise in active surveillance and watchful waiting in patients with intermediate-risk prostate cancer.
Read More
Controversy Swirls Around the Use of CDK4/6 Inhibitors as Adjuvant Breast Cancer Therapy
January 15th 2025CDK4/6 inhibitors like abemaciclib and ribociclib improve invasive disease-free survival in breast cancer trials, but controversy surrounds study designs, bias, and cost-effectiveness, raising critical questions about their clinical benefit.
Read More
